Innoplexus is a leading global AI-based platform for drug discovery and development with over 250 employees and 120+ patent applications including 41 granted patents in artificial intelligence, machine learning, and blockchain technologies. Innoplexus' solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby, facilitating continuous, informed decision-making for its customer base at an unprecedented speed. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, as well as Iselin, and San Francisco, United States.

Contact

Secarna Pharmaceuticals GmbH & Co. KG

Alexander Gebauer, MD, PhD CEO alexander.gebauer@secarna.com

Secarna Pharmaceuticals GmbH & Co. KG Am Klopferspitz 19 82152 Planegg/Martinsried Tel.: +49 (0)89 215 46 375

For media enquiries:

Anne Hennecke/Vera Lang MC Services AG secarna@mc-services.eu Tel.: +49 (0)211.52 92 52 15

-----------------------------------------------------------------------------------------------------------------------

2021-10-25 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

1243198 2021-10-25

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1243198&application_name=news

(END) Dow Jones Newswires

October 25, 2021 09:00 ET (13:00 GMT)